Chilling the ear canal during cochlear implant surgery may protect residual hearing

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Potential participants for the study are patients who have been diagnosed with severe to profound hearing loss (HL) and plan to undergo cochlear implantation (CI) at the University of Miami. The cochlear implant surgery, pre and post-surgical care, and activation and programming of the implant are part of the participants' standard of care. If the inclusion criteria are met (age 18 years and older, equal number of men and women, profound sensorineural hearing loss (for safety study n=6) and residual hearing (see criteria below) from pre-surgical auditory brainstem response (ABR) (for efficacy study n=48), equal numbers of CI devices from all 3 manufactures and English or Spanish speakers the patient will be approached by the study personnel and will be asked to participate in the study. Exclusion Criteria: Subjects under 18 years of age. Subjects not meeting functional hearing requirements. Types of CI devices: The study will enroll patients receiving CI devices from all three manufactures. 1. Advanced Bionics (FDA indications - severe to profound sensorineural hearing loss (greater than or equal to 70 dB HL) 1. HiRes Ultra 3D slim J 2. HiRes Ultra 3D midScala 2. Cochlear Corporation (FDA indications - moderate to profound sensorineural hearing loss; sentence recognition less than or equal to 50% in the ear to be implanted AND less than or equal to 60% in the contralateral ear 1. CI632 2. CI622 3. CI612 3. Med-EL (moderately-severe to severe sensorineural hearing loss (greater than or equal to 65 db HL). 1. Synchrony 2 Flex soft 2. Synchrony 2 Flex28 3. Synchrony 2 Flex 24 4. Synchrony 2 Compressed 5. Synchrony 2 Medium Additional patients receiving devices not listed here may be eligible as the criteria by manufacturer change.